BLOO7 schreef op 13 juni 2019 15:39:
But new Gilead Sciences CEO Daniel O'Day said on his company's Q1 conference call that he wants to "accelerate some of the plans around filgotinib." Gilead plans to talk with the FDA. It seems possible that the big biotech could file for U.S. approval of filgotinib sooner than anticipated. That would be great news for Galapagos. Filgotinib isn't Galapagos' only promising pipeline candidate, though. The biotech is evaluating GLPG1690 in a late-stage study targeting idiopathic pulmonary fibrosis (IPF). It's working with French drugmaker Servier on a phase 2 study of GLPG1972 in treating osteoarthritis. In addition, Galapagos and partner MorphoSys are conducting phase 1 and phase 2 studies evaluating MOR106 in treating atopic dermatitis.
www.fool.com/investing/2019/05/19/bet...Als het hem mocht lukken, dan weet ik niet of dit voor Galapagos goed nieuws zou betekenen. Het muurtje (de koers) is nog niet hoog genoeg.